TriSalus Life Sciences Q1 revenue falls 2.9%, misses estimates

TriSalus Life Sciences

12/05/2026 21:10

Overview

US oncology device maker's Q1 revenue fell 2.9% yr/yr, missing analyst expectations

Company posted net income of $1.5 mln, reversing a loss from prior year

TriSalus raised $46 mln in equity to fund commercial expansion and pipeline development

Outlook

TriSalus revises 2026 revenue guidance to $54 mln-$57 mln

Company says updated outlook reflects commercial expansion and delayed FDA clearance for TriNav Advance

Company believes long-term growth opportunity for PEDD platform remains substantial

Result Drivers

COMMERCIAL EXPANSION - Co said lower Q1 revenue was primarily due to commercial expansion initiatives

HIGHER OPERATING EXPENSES - Increased operating losses were mainly driven by higher sales and marketing expenses related to commercial expansion and increased stock-based compensation

GROSS MARGIN IMPROVEMENT - Gross margin rose due to lower average cost per TriNav unit

Company press release: ID:nBw8cZQV2a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$8.90 mln
$10.44 mln (5 Analysts)
Q1 Gross Profit
$7.67 mln
Q1 Income from Operations
-$8.41 mln
Q1 Pretax Profit
$1.54 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for TriSalus Life Sciences Inc is $10.00, about 120.3% above its May 11 closing price of $4.54

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)